Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.


The conversation around Decentralized Trials (DCTs) usually focuses on the technology. Patients meet with investigators via telehealth and share data remotely using wearable devices, virtual questionnaires, and electronic outcomes assessments. However, there are still times in the trial when visits need a human touch, and this is where mobile nursing & phlebotomy units fill the gap.
Mobile nurses and phlebotomists enable a more personalized, patient-centric experience, ensuring study participants get all the one-on-one support they need from the comfort of their own homes. Often, this is a good fit for patients with caregivers or trials that have many required visits.
They also bring a unique set of qualifications to the team. Mobile nursing & phlebotomy units aren’t just conventional nurses dispatched into the field. They are specialized professionals trained to perform specific research activities in a home environment which makes clinical trials participation more attractive and strengthens patient engagement.
Mobile nurse and phlebotomy training is key to delivering a safe and effective DCT experience. Additionally, the goal is for the experience to be personable. This is accomplished by continuity of care- scheduling the same nurse or phlebotomist to the same patient over the course of the trial. However, because it is such a new role, many sites and sponsors are still uncertain about how mobile nurses and phlebotomists work, who is responsible for them, and how they are vetted and paid.
To clear up that confusion, IQVIA’s Research Nursing and Phlebotomy Solutions (RNPS) explored common myths about mobile nursing & phlebotomy, and the truth about how these teams work.
To learn more about IQVIA’s Research Nursing and Phlebotomy Solutions visit here.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
The human touch in tech-enabled trials